Drugs / INO-3106
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02241369 | May 2014 → Sep 2018 | preneoplastic lesion | Inovio Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-3106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02241369 ↗ |
| Modality | Vaccine | “INO-3106 alone or in combination with INO-9012 DNA vaccines” NCT02241369 ↗ |
| Route | Other | “delivered by Electroporation” NCT02241369 ↗ |